CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a b ...

- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to develop a first-of-its-kind assay to assess sabirnetug's binding to amyloid beta oligomers (AβOs) in Alzheimer's disease - Company on track to initiate Phase 2 trial evaluating sabirnetug in the first half of 2024 and Phase 1 subcutaneous study in mid-2024 CHARLOTTESVILLE, Va., March 08, 2024 (GLOBE NEWSWIRE) -- Acumen ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Acumen Pharmaceuticals, Inc. (ABOS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Acumen Pharmaceuticals, Inc. is one of 1065 individual stocks ...

CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O'Connell, Chief Executive Officer. Dr. Doherty's responsibilities will include oversight of clin ...

As investors, we are often looking to diversify our portfolios. Especially with the wild AI craze in the past year, many investors already hold positions in AI or other technology companies. Adding a variety of stocks from different sectors in your portfolio can help reduce risk. It lessens your dependence on returns in one sector. Diversification with the top healthcare stocks to buy can help spread out your risk in case any one sector collapses.Although healthcare stocks aren’t discussed as much right now ...

Aging stocks (or longevity stocks) are drawing attention from investors for obvious reasons. The Baby Boomer generation is now almost fully retired, and Gen X is right on its heels. It is a profitable trend that’s not going away anytime soon.There are many ways to invest in an aging population. An obvious choice is healthcare stocks. The advancements in medical technology allow individuals to enjoy a better quality of life for much longer.Of course, as many Gen X and Millennial children can attest to, that ...

CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast may be accessed under the Investors t ...

Q3 2023 Financial Results & Business Update November 13, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking stateme ...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2023 Earnings Conference Call November 13, 2023 08:00 AM ET Company Participants Alex Braun - Head-IR Daniel O'Connell - CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Thomas Shrader - BTIG Pete Stavropoulos - Cantor Fitzgerald Colin Bristow - UBS Presentation Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharma Third Quarter 2023 Conference Call and Webcast ...

PART I. FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Unaudited financial statements show total assets increased to **$286.4 million** due to a public offering, with a **$35.9 million** net loss for the first nine months of 2023 Condensed Balance Sheet Highlights (in thousands) | Account | Sep 30, 2023 | Dec 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $94,917 | $130,101 | | Marketable securities (short & long-term) | $187,787 | $63,341 | | **Total assets** | **$286,371** | **$196,587** | | Total liabilities | $6,098 | $7,812 | | **Total stockholders' equity** | **$280,273** | **$188,775** | Condensed Statement of Operations Highlights (in thousands, except per share data) | Metric | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | | Research and development | $29,025 | $21,615 | | General and administrative | $13,627 | $9,374 | | **Loss from operations** | **($42,652)** | **($30,989)** | | **Net loss** | **($35,874)** | **($29,990)** | | Net loss per common share | ($0.79) | ($0.74) | Condensed Statement of Cash Flows Highlights (in thousands) | Cash Flow Activity | Nine Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($34,750) | ($23,950) | | Net cash (used in) provided by investing activities | ($122,864) | $59,605 | | Net cash provided by (used in) financing activities | $122,619 | ($277) | - In July 2023, the company completed a public offering, issuing 16,774,193 shares of common stock at **$7.75 per share**, resulting in net proceeds of **$122.3 million** after expenses[31](index=31&type=chunk) - Subsequent to the quarter end, the company entered a license agreement with Halozyme for ENHANZE® technology and a Loan and Security Agreement for up to **$50.0 million** in term loans[80](index=80&type=chunk)[82](index=82&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses ACU193's clinical progress, a **38%** rise in operating expenses, and strengthened liquidity from recent financing, extending cash runway to 2026 - The company announced **positive topline results** from its **Phase 1 INTERCEPT-AD trial** for ACU193 in July 2023, meeting primary objectives for safety and tolerability and showing evidence of target engagement in the brain, with plans to initiate a **Phase 2/3 clinical study** in the first half of 2024[89](index=89&type=chunk)[91](index=91&type=chunk)[94](index=94&type=chunk) Comparison of Operating Expenses (Nine Months Ended Sep 30, in thousands) | Expense Category | 2023 | 2022 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $29,025 | $21,615 | $7,410 | 34% | | General and administrative | $13,627 | $9,374 | $4,253 | 45% | | **Total operating expenses** | **$42,652** | **$30,989** | **$11,663** | **38%** | - The **$7.4 million** increase in R&D expenses was primarily driven by higher personnel costs, services from contractors and consultants, and costs associated with planning for the upcoming Phase 2 clinical trial[116](index=116&type=chunk) - The **$4.3 million** increase in G&A expenses was mainly due to a **$3.5 million** rise in personnel costs, which included a **$1.6 million** increase in non-cash stock compensation, along with higher consulting and professional fees[117](index=117&type=chunk) - As of September 30, 2023, the company had **$282.7 million** in cash, cash equivalents, and marketable securities, with capital expected to fund operations and expenditures into the **second half of 2026** after a subsequent **$30.0 million** loan tranche received in November 2023[99](index=99&type=chunk)[121](index=121&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a "smaller reporting company," Acumen Pharmaceuticals is not required to provide market risk disclosures - Acumen Pharmaceuticals is not required to provide quantitative and qualitative disclosures about market risk because it qualifies as a "smaller reporting company" under SEC regulations[140](index=140&type=chunk) [Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Management confirmed effective disclosure controls and no material changes to internal controls over financial reporting as of September 30, 2023 - Based on an evaluation as of September 30, 2023, the company's management, including the principal executive and financial officers, concluded that disclosure controls and procedures were **effective**[142](index=142&type=chunk) - There were no changes in the company's internal control over financial reporting during the quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, these controls[144](index=144&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=28&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings that would adversely affect its business - As of the filing date, the company is not subject to any material legal proceedings[148](index=148&type=chunk) [Risk Factors](index=28&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K - There have been no material changes to the risk factors as described in the company's Annual Report on Form 10-K for the year ended December 31, 2022[149](index=149&type=chunk) [Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities](index=28&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%2C%20Use%20of%20Proceeds%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company reports no unregistered equity sales or repurchases, with no material change in the planned use of IPO proceeds - The company reports no unregistered sales of equity securities or issuer purchases of its equity securities for the period[149](index=149&type=chunk)[150](index=150&type=chunk) - There has been no material change in the planned use of the **$168.6 million** in net proceeds from the company's IPO, which closed in July 2021[150](index=150&type=chunk) [Defaults Upon Senior Securities](index=28&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This item is not applicable to the company - Not applicable[151](index=151&type=chunk) [Mine Safety Disclosures](index=28&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[151](index=151&type=chunk) [Other Information](index=28&type=section&id=Item%205.%20Other%20Information) The company secured up to **$50.0 million** in term loans via a Loan and Security Agreement on November 10, 2023, for working capital - On November 10, 2023, the company entered into a Loan and Security Agreement providing up to **$50.0 million** in term loans[152](index=152&type=chunk) - The loan consists of a first tranche of **$30.0 million** funded at closing and a second tranche of up to **$20.0 million** available subject to lender review and approval[152](index=152&type=chunk) - The loan bears a variable interest rate, matures on **November 1, 2027** (extendable to **2028**), and is secured by substantially all company assets, excluding intellectual property[153](index=153&type=chunk) [Exhibits](index=30&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including officer certifications and XBRL documents - The report includes a list of exhibits filed, such as officer certifications under Sections 302 and 906 of the Sarbanes-Oxley Act and XBRL data files[158](index=158&type=chunk)